Literature DB >> 8104858

Overexpression of HER2/neu oncogene in human pancreatic carcinoma.

Y Yamanaka1, H Friess, M S Kobrin, M Büchler, J Kunz, H G Beger, M Korc.   

Abstract

The HER2/neu oncogene encodes a transmembrane protein that possesses intrinsic tyrosine kinase activity. Its overexpression has been associated with the malignant phenotype. In this study we examined HER2/neu expression in the normal and cancerous human pancreas. In the normal pancreas HER2/neu immunostaining was observed in acinar and ductal cells. HER2/neu immunoreactivity was expressed in 34 of 76 (45%) pancreatic carcinomas. There was a significant correlation between tumors with well-differentiated histology and HER2/neu expression. Northern blot analysis demonstrated HER2/neu mRNA expression in the normal pancreas and in situ hybridization confirmed its distribution in both acinar and ductal cells. In cancer tissues Northern blot analysis indicated that HER2/neu mRNA levels were elevated in 13 of 25 (52%) of the tumors in comparison with the normal tissues. In addition, in situ hybridization demonstrated a strong but heterogenous distribution of mRNA grains in these tumors. Southern blot analysis did not demonstrate HER2/neu gene amplification in any of the tumors. These data indicate that the HER2/neu protein is synthesized in the normal exocrine pancreas and is frequently overexpressed in well-differentiated adenocarcinomas of the pancreas as a result of increased HER2/neu mRNA levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104858     DOI: 10.1016/0046-8177(93)90194-l

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  60 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 2.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  The challenge of pancreatic cancer.

Authors:  James L Abbruzzese
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 4.  Biology and management of pancreatic cancer.

Authors:  Paula Ghaneh; Eithne Costello; John P Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 5.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

6.  Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.

Authors:  Antonio Lozano-Leon; Begona Vieites Perez-Quintela; Julio Iglesias-García; Jose Lariño-Noia; Evaristo Varo; Jeronimo Forteza; J Enrique Domínguez-Muñoz
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

7.  Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells.

Authors:  T Oikawa; J Hitomi; A Kono; E Kaneko; K Yamaguchi
Journal:  Int J Pancreatol       Date:  1995-08

Review 8.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors:  A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  EGFR and HER2 inhibition in pancreatic cancer.

Authors:  Naomi Walsh; Susan Kennedy; AnneMarie Larkin; Brendan Corkery; Lorraine O'Driscoll; Martin Clynes; John Crown; Norma O'Donovan
Journal:  Invest New Drugs       Date:  2012-10-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.